Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Phase 2
Not yet recruiting
- Conditions
- Recurrent or Metastatic Nasopharyngeal CancerPatients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06892431
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Phase 2
Not yet recruiting
- Conditions
- Solid TumorsChildrenAdolescents
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-08
- Target Recruit Count
- 49
- Registration Number
- NCT06761417
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Not Applicable
Recruiting
- Conditions
- Relapsed/Refractory Acute Myeloid LeukaemiaMyeloid Malignancy
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06621212
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
Phase 2
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 42
- Registration Number
- NCT06621199
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 108
- Registration Number
- NCT06594640
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.
Phase 2
Recruiting
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Drug: Temozolomide+Irinotecan+Vincristine
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Yizhuo Zhang
- Target Recruit Count
- 110
- Registration Number
- NCT06514313
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
Early Phase 1
Recruiting
- Conditions
- t(8;21)AMLNeoantigen
- Interventions
- Biological: targeted AML1-ETO neoantigen cytotoxic T cells (CTL)
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- BGI, China
- Target Recruit Count
- 16
- Registration Number
- NCT06499025
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Guangdong, China
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
Phase 2
Recruiting
- Conditions
- Relapsed/Refractory Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 89
- Registration Number
- NCT06489808
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Phase 2
Recruiting
- Conditions
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Interventions
- Drug: PD-1 Inhibitors
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Ming-Yuan Chen
- Target Recruit Count
- 32
- Registration Number
- NCT06472713
- Locations
- 🇨🇳
The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Phase 2
Recruiting
- Conditions
- Relapse Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Target Recruit Count
- 30
- Registration Number
- NCT06447090
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, China, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath